Related Experiment Videos
Structure activity studies on somatostatin.
Clinical Endocrinology
|January 1, 1976
Summary
Synthetic somatostatin analogues reveal key structural needs for inhibiting growth hormone release in rats. Specific modifications show that the peptide ring size is not critical for maintaining biological activity.
Area of Science:
- Endocrinology
- Pharmacology
- Biochemistry
Background:
- Somatostatin is a peptide hormone with diverse physiological roles, including the regulation of growth hormone secretion.
- Understanding the structure-activity relationship of somatostatin analogues is crucial for developing targeted therapeutics.
Purpose of the Study:
- To investigate the structural requirements of somatostatin for suppressing growth hormone secretion in rats.
- To evaluate the impact of specific amino acid deletions on the biological activity of somatostatin analogues.
Main Methods:
- Synthesis and characterization of seven novel somatostatin analogues.
- In vivo studies in rats to measure plasma levels of growth hormone, insulin, and glucagon following analogue administration.
Main Results:
- The size of the somatostatin ring is not essential for maintaining activity.
- Peptides with deletions at serine-13, lysine-4, or asparagine-5 retained significant biological activity.
- A specific analogue, des-Ala1, Gly2, Asn5-somatostatin, effectively lowered plasma growth hormone and insulin without significantly altering glucagon levels.
Conclusions:
- Structural modifications, particularly deletions of specific amino acids, can yield somatostatin analogues with retained or altered biological functions.
- The analogue des-Ala1, Gly2, Asn5-somatostatin represents a promising candidate for further investigation due to its selective effects on hormone levels.